Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q2 2023 · 10-Q
Revenue$2.89M$2.89M−54.6% vs Q2 2022 Net Income-$40.29M-$40.29MN/M vs Q2 2022 EPS Diluted-$0.56-$0.56N/M vs Q2 2022 Operating Income-$44,094,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$40,044,000N/M Margins · derivedOperating margin-1527.3%−674.9 pt vs Q2 2022
Net margin-1395.6%−555.4 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 2, 2023 · 33 d after period end